We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BASFY to Divest Optical Brightening Agent Business to Catexel
Read MoreHide Full Article
Key Takeaways
BASFY signed a deal to divest its optical brightening agent business as part of its Winning Ways strategy.
The sale includes the Monthey, Switzerland facility and about 80 employees, with financial terms undisclosed.
Catexel will integrate the business into its specialty chemicals portfolio, with closing expected in Q1 2026.
BASF SE (BASFY - Free Report) has signed a definitive agreement to divest its optical brightening agent business to Catexel, aligning with the company’s ongoing portfolio transformation under its ‘Winning Ways’ strategy. Optical brightening agents — specialty ingredients used predominantly in laundry detergent formulations to enhance whiteness and brightness — have been part of BASFY’s Care Chemicals division.
The transaction includes the international business unit, notably the production facility at Monthey in Switzerland and around 80 employees, and reflects BASF SE’s focus on strategically prioritizing businesses that are more closely integrated into its core value chains.
The companies did not disclose the financial details of the transaction, which is subject to standard regulatory and closing conditions, with the deal anticipated to close in the first quarter of 2026.
BASFY emphasized that the divestment supports its strategy to actively manage its portfolio and prioritize key segments, while entrusting the business to a new owner with dedicated focus and capabilities to further develop its potential. Catexel, the Care Chemicals platform of the International Chemical Investors Group, will integrate the optical brightening agent business into its expanding portfolio of specialty chemicals for detergents, cleaning products, personal care and industrial applications.
Catexel stated that the acquisition represents a strategic milestone, providing a foundation for further growth and innovation by leveraging the Monthey facility and the experienced workforce. BASF SE affirmed that it will remain a leading supplier and innovator of ingredients for the home care and industrial & institutional cleaning markets even after the closing of the divestiture.
Shares of BASFY have gained 8.9% in the past six months against the industry’s 12.4% decline.
Image Source: Zacks Investment Research
BASFY’s Zacks Rank & Key Picks
BASFY currently carries a Zacks Rank of #3 (Hold).
The Zacks Consensus Estimate for LXU’s current-year earnings is pegged at 36 cents per share, indicating a 57% year-over-year increase. Its earnings beat the Zacks Consensus Estimates in two of the trailing four quarters and missed twice, with the average earnings surprise of 141.3%.
The Zacks Consensus Estimate for EQX’s current fiscal-year earnings stands at 54 cents per share, reflecting a 170% year-over-year increase. Its earnings beat the Zacks Consensus Estimates in two of the trailing four quarters and missed twice, with the average earnings surprise of 87%.
The Zacks Consensus Estimate for OR’s current fiscal-year earnings is pegged at 83 cents per share, indicating a 60% year-over-year increase. Its earnings beat the Zacks Consensus Estimates in three of the trailing four quarters and missed once, with the average earnings surprise of 4%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BASFY to Divest Optical Brightening Agent Business to Catexel
Key Takeaways
BASF SE (BASFY - Free Report) has signed a definitive agreement to divest its optical brightening agent business to Catexel, aligning with the company’s ongoing portfolio transformation under its ‘Winning Ways’ strategy. Optical brightening agents — specialty ingredients used predominantly in laundry detergent formulations to enhance whiteness and brightness — have been part of BASFY’s Care Chemicals division.
The transaction includes the international business unit, notably the production facility at Monthey in Switzerland and around 80 employees, and reflects BASF SE’s focus on strategically prioritizing businesses that are more closely integrated into its core value chains.
The companies did not disclose the financial details of the transaction, which is subject to standard regulatory and closing conditions, with the deal anticipated to close in the first quarter of 2026.
BASFY emphasized that the divestment supports its strategy to actively manage its portfolio and prioritize key segments, while entrusting the business to a new owner with dedicated focus and capabilities to further develop its potential. Catexel, the Care Chemicals platform of the International Chemical Investors Group, will integrate the optical brightening agent business into its expanding portfolio of specialty chemicals for detergents, cleaning products, personal care and industrial applications.
Catexel stated that the acquisition represents a strategic milestone, providing a foundation for further growth and innovation by leveraging the Monthey facility and the experienced workforce. BASF SE affirmed that it will remain a leading supplier and innovator of ingredients for the home care and industrial & institutional cleaning markets even after the closing of the divestiture.
Shares of BASFY have gained 8.9% in the past six months against the industry’s 12.4% decline.
BASFY’s Zacks Rank & Key Picks
BASFY currently carries a Zacks Rank of #3 (Hold).
Some better-ranked stocks in the Basic Materials space are LSB Industries, Inc. (LXU - Free Report) , Equinox Gold, Corp. (EQX - Free Report) and OR Royalties, Inc. (OR - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
The Zacks Consensus Estimate for LXU’s current-year earnings is pegged at 36 cents per share, indicating a 57% year-over-year increase. Its earnings beat the Zacks Consensus Estimates in two of the trailing four quarters and missed twice, with the average earnings surprise of 141.3%.
The Zacks Consensus Estimate for EQX’s current fiscal-year earnings stands at 54 cents per share, reflecting a 170% year-over-year increase. Its earnings beat the Zacks Consensus Estimates in two of the trailing four quarters and missed twice, with the average earnings surprise of 87%.
The Zacks Consensus Estimate for OR’s current fiscal-year earnings is pegged at 83 cents per share, indicating a 60% year-over-year increase. Its earnings beat the Zacks Consensus Estimates in three of the trailing four quarters and missed once, with the average earnings surprise of 4%.